Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1632 1638
This examiner grants 41% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17910776 | METHODS FOR GENERATING ENGINEERED MEMORY-LIKE NK CELLS AND COMPOSITIONS THEREOF | Final Rejection | Dana-Farber Cancer Institute, Inc. |
| 18437160 | GENETICALLY MODIFIED MSC AND THERAPEUTIC METHODS | Final Rejection | The Regents of the University of California |
| 17351113 | METHODS FOR THE TREATMENT OF DANON DISEASE AND OTHER DISORDERS OF AUTOPHAGY | Final Rejection | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA |
| 17640585 | DEVELOPMENT OF EMBRYONIC-LIKE TISSUE FROM STEM CELLS | Final Rejection | The Regents of the University of Michigan |
| 18899268 | Multiplexed Genome Editing | Non-Final OA | President and Fellows of Harvard College |
| 18089267 | HUMANIZED RODENTS FOR TESTING THERAPEUTIC AGENTS | Final Rejection | Regeneron Pharmaceuticals, Inc. |
| 17676338 | NON-HUMAN ANIMALS HAVING AN IMMUNOGLOBULIN HEAVY CHAIN VARIABLE REGION THAT INCLUDES AN ENGINEERED DIVERSITY CLUSTER AND USES THEREOF | Final Rejection | Regeneron Pharmaceuticals, Inc. |
| 17113485 | GENETICALLY MODIFIED MICE THAT EXPRESS HUMANIZED IgG1 LACKING A CH1 DOMAIN AND HUMANIZED UNIVERSAL LIGHT CHAIN | Final Rejection | Regeneron Pharmaceuticals, Inc. |
| 18838519 | Cerebrovascular-Tumor-On-A-Chip | Non-Final OA | Ohio State Innovation Foundation |
| 17910992 | NK CELLS AND USES THEREOF FOR TREATMENT OF MICROBIAL INFECTIONS | Final Rejection | RESEARCH INSTITUTE AT NATIONWIDE CHILDREN'S HOSPITAL |
| 16624081 | A METHOD OF TREATING EPIDERMOLYSIS BULLOSA USING MUSE CELLS | Final Rejection | TOHOKU UNIVERSITY |
| 18619199 | METHOD FOR INDUCING DEDIFFERENTIATION OF ADIPOCYTES | Non-Final OA | City University of Hong Kong |
| 18033442 | MOUSE MODEL FOR BIO-IMAGING OF INFLAMMATORY SIGNALS, PREPARATION METHOD THEREFOR AND USE THEREOF | Final Rejection | SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION |
| 18727953 | COMPOSITIONS USEFUL IN TREATMENT OF METACHROMATIC LEUKODYSTROPHY | Non-Final OA | The Trustees of the University of Pennsylvania |
| 18052113 | TRANSGENIC RABBIT WITH COMMON LIGHT CHAIN | Non-Final OA | Hoffmann-La Roche Inc. |
| 17264752 | GENE THERAPY METHODS TO CONTROL ORGAN FUNCTION | Non-Final OA | Cornell University |
| 17345773 | Methods for Cardiac Fibroblast Differentiation of Human Pluripotent Stem Cells | Final Rejection | Wisconsin Alumni Research Foundation |
| 18737201 | SELF-INACTIVATING LENTIVIRAL VECTOR ENCODING BETA- OR GAMMA-GLOBIN | Non-Final OA | Children's Hospital Medical Center |
| 18197151 | GENETICALLY EDITED ALBINO-RED GERMLINES OF TILAPIA FISH | Non-Final OA | The State of Israel, Ministry of Agriculture & Rural Development, Agricultural Research Organization |
| 18609867 | TRANSGENIC MOUSE EXPRESSING HUMAN CEREBLON | Non-Final OA | CELGENE CORPORATION |
| 17825784 | TOOLS AND METHODS FOR USING CELL DIVISION LOCI TO CONTROL PROLIFERATION OF CELLS | Non-Final OA | Sinai Health System |
| 15556146 | TOOLS AND METHODS FOR USING CELL DIVISION LOCI TO CONTROL PROLIFERATION OF CELLS | Final Rejection | Sinai Health System |
| 18019999 | SINGLE GENERATION TARGETED GENE INTEGRATION | Non-Final OA | The Jackson Laboratory |
| 17378954 | COMPOSITION FOR TREATING LUNG CANCER, PARTICULARLY OF NON-SMALL LUNG CANCERS (NSCLC) | Non-Final OA | CureVac AG |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy